April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Alterations in serum vascular endothelial growth factor after intraocular administration of antiVEGF drugs, is there an association with safety outcomes?
Author Affiliations & Notes
  • Usha Chakravarthy
    Ctr for Vascular & Vision Sciences, Queens University of Belfast, Belfast, United Kingdom
  • Chris Rogers
    Clinical Trials and Evaluation Unit, Bristol Heart Institute, Bristol, United Kingdom
  • Barney Reeves
    Clinical Trials and Evaluation Unit, Bristol Heart Institute, Bristol, United Kingdom
  • Lauren Scott
    Clinical Trials and Evaluation Unit, Bristol Heart Institute, Bristol, United Kingdom
  • Simon P Harding
    Department of Eyes and Vision, University of Liverpool, Liverpool, United Kingdom
  • Susan M Downes
    Ophthalmology, Oxford University Hospitals, Oxford, United Kingdom
  • Andrew Lotery
    Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom
  • Footnotes
    Commercial Relationships Usha Chakravarthy, Alimera Sciences (C), Allergan (C), Bayer (C), Novartis (C), Roche (C); Chris Rogers, None; Barney Reeves, None; Lauren Scott, None; Simon Harding, None; Susan Downes, Novartis (C); Andrew Lotery, Bayer (C), Novartis (C)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 871. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Usha Chakravarthy, Chris Rogers, Barney Reeves, Lauren Scott, Simon P Harding, Susan M Downes, Andrew Lotery, ; Alterations in serum vascular endothelial growth factor after intraocular administration of antiVEGF drugs, is there an association with safety outcomes?. Invest. Ophthalmol. Vis. Sci. 2014;55(13):871.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

To investigate whether the fall in serum vascular endothelial growth factor (VEGF) levels after intraocular administration of anti VEGF drugs in the “alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN) clinical trial, is related to safety outcomes.

 
Methods
 

IVAN participants were seen monthly for 2-years. VEGF levels were measured in serum samples taken at visits 0, 1, 11, 12, 23 and 24. We compared the change in VEGF levels from visit 0 to visits 1, 12 and 24 by drug and treatment regimen and examined the relationship between the change in VEGF levels after one treatment (i.e. between visits 0 and 1) and the subsequent occurrence of a serious adverse event (SAE) not previously known to be associated with anti-VEGF therapy (i.e. we excluded cardiovascular-related SAEs). Analyses were adjusted for patient demography and past history.

 
Results
 

Data on VEGF levels were available for 506 IVAN participants. VEGF levels declined over time in all groups, but the decline was greater with bevacizumab than ranibizumab (see Figure). No statistically significant associations were detected between SAE occurrence and the change in VEGF level (p=0.92) or the amount of circulating VEGF (p=0.95). Similarly no association with drug or treatment frequency was found (p=0.80 and p=0.29 respectively).

 
Conclusions
 

These preliminary analyses found no association between the occurrence of an SAE and circulating VEGF levels. Work is ongoing to further classify SAEs into those that could and could not plausibly be influenced by VEGF levels, in order to examine whether an association exists for this subgroup of events.

 
 
change in serum VEGF. Median and interquartile range at baseline, 12 and 24 months by drug and by treatment frequency
 
change in serum VEGF. Median and interquartile range at baseline, 12 and 24 months by drug and by treatment frequency
 
Keywords: 412 age-related macular degeneration • 748 vascular endothelial growth factor • 462 clinical (human) or epidemiologic studies: outcomes/complications  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×